undamentalytics Newsletter
Sign in

Onemednet Corp (ONMD) stock

Add to watchlist

Add holding +

NASDAQ: ONMD Nasdaq Health Care Technology

D Fundamentals grade

Onemednet Corp is a US-listed company in the health care technology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Onemednet Corp is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Onemednet Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 2 selling14 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds11 adding, 8 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Onemednet files

Where Onemednet stands after its latest 10-Q

Onemednet has little or no product revenue yet; it used $7m of cash in the twelve months to June 2026. That growth ranks 1 of 19 among the health care technology companies we cover. The diluted share count is up 62.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 5 financial-health checks.

Our model value for Onemednet is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Onemednet Corp's trailing-twelve-month revenue grew 216.5% year on year, with a free-cash-flow margin of -473.4%. Where it stands out: change in growth rate of +68.6pp ranks 1 of 23 health care technology companies we cover. Where it lags: gross margin of -68.8% ranks 14 of 14 health care technology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 216.5% (+68.6pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 216.5% over the last 12 months, against a median of 8.8% for health care technology companies we cover.
  • Growth speeding up. The growth rate is 68.6 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 1334.5 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -695.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -473.4% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 173.1% of revenue, against a median of 9.7% for health care technology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 62.6% in a year.
  • High sales multiple. The shares trade at 161 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 130% and a beta of 0.7 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Revenue
$0m, up 88.4% on a year earlier

Onemednet's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.4%
  • 1 week-4.3%
  • 1 month-20.6%
  • This year-61.1%
  • 1 year-79.8%
  • 5 years-95.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.5M
Operating margin
-695.7%
Net margin
-584.2%
EPS (TTM, diluted)
$-0.16

Growth

Revenue growth
+216.5%
Change in growth rate
+68.6 pts
Share count change
+62.6%

Cash

Free cash flow (TTM)
-$6.9M
FCF margin
-473.4%
Stock pay % of revenue
173.1%

Earnings

Last results
May 23, 2024

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Governance
  3. Leadership
  4. Insider trade
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Onemednet Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Onemednet Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$0.0–$0.1 Left out: out of range vs price (0.00x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Onemednet Corp with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$104.40$8.10$13.60$11.00$4.28
Market value$1.7bn$236m$382m$490m$234m
+ Net debt (− = net cash)$26m$2m$10m$389000$343000
Enterprise value$1.7bn$238m$392m$490m$235m
Multiples
Price / sales n/mn/mn/mn/m161.0x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Onemednet Corp: too few analysts cover it.

Positioning

Short interest
4.9%
of tradable shares
Days to cover
2.2
at average volume
Short interest, 1 month
+64%
to October 15, 2026
Held by institutions
30%
of shares
Held by insiders
72.1%
of shares
Employees
22
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
ONMD+3%−92%+68%−19%−61%
Industry peers (median)−67%−16%−24%−28%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
ONMD83%67%50%42%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
ONMD−1%−93%−78%−77%−68%
S&P 500−25%−10%−8%−19%−9%

Worst fall since June 24, 2021: 97% from October 9, 2023 to June 13, 2025. Getting back needed a 3451% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.93 – $19.50
From 52-week high
−78.1%
vs 50-day average
−22.4%
vs 200-day average
−40.4%
Volatility (1 year)
130%
Beta vs S&P 500
0.68

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±369.4%
After a week
1 up, 0 down
typical move ±393.9%
After a month
1 up, 0 down
typical move ±86.9%
Results releasedNext dayS&P 500 next day5 days21 days
May 23, 2024 +369.4% −0.1% +393.9% +86.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Onemednet Corp in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Onemednet Corp
$0 $500K $1M $1.5M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $963K Revenue (TTM), FY23 Q4: $1M Revenue (TTM), FY24 Q1: $1.1M Revenue (TTM), FY24 Q2: $1.1M Revenue (TTM), FY24 Q3: $957K Revenue (TTM), FY24 Q4: $643K Revenue (TTM), FY25 Q1: $532K Revenue (TTM), FY25 Q2: $460K Revenue (TTM), FY25 Q3: $495K Revenue (TTM), FY25 Q4: $1.4M Revenue (TTM), FY26 Q1: $1.3M Revenue (TTM), FY26 Q2: $1.5M $1.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $963K
FY23 Q4 $1M
FY24 Q1 $1.1M
FY24 Q2 $1.1M
FY24 Q3 $957K
FY24 Q4 $643K
FY25 Q1 $532K
FY25 Q2 $460K
FY25 Q3 $495K
FY25 Q4 $1.4M
FY26 Q1 $1.3M
FY26 Q2 $1.5M
Revenue growth, TTM YoY Onemednet Corp
-100% 0% 100% 200% 300% FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue growth, TTM YoY, FY24 Q3: -0.6% Revenue growth, TTM YoY, FY24 Q4: -38.1% Revenue growth, TTM YoY, FY25 Q1: -51.1% Revenue growth, TTM YoY, FY25 Q2: -59.7% Revenue growth, TTM YoY, FY25 Q3: -48.3% Revenue growth, TTM YoY, FY25 Q4: 111.5% Revenue growth, TTM YoY, FY26 Q1: 147.9% Revenue growth, TTM YoY, FY26 Q2: 216.5% 216.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q3 -0.6%
FY24 Q4 -38.1%
FY25 Q1 -51.1%
FY25 Q2 -59.7%
FY25 Q3 -48.3%
FY25 Q4 111.5%
FY26 Q1 147.9%
FY26 Q2 216.5%
Operating margin (TTM) Onemednet Corp
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -1117.0% Operating margin (TTM), FY23 Q4: -657.8% Operating margin (TTM), FY24 Q1: -686.9% Operating margin (TTM), FY24 Q2: -731.8% Operating margin (TTM), FY24 Q3: -915.3% Operating margin (TTM), FY24 Q4: -1494.1% Operating margin (TTM), FY25 Q1: -1828.9% Operating margin (TTM), FY25 Q2: -2030.2% Operating margin (TTM), FY25 Q3: -1866.3% Operating margin (TTM), FY25 Q4: -706.2% Operating margin (TTM), FY26 Q1: -753.0% Operating margin (TTM), FY26 Q2: -695.7% -695.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -1117.0%
FY23 Q4 -657.8%
FY24 Q1 -686.9%
FY24 Q2 -731.8%
FY24 Q3 -915.3%
FY24 Q4 -1494.1%
FY25 Q1 -1828.9%
FY25 Q2 -2030.2%
FY25 Q3 -1866.3%
FY25 Q4 -706.2%
FY26 Q1 -753.0%
FY26 Q2 -695.7%
FCF margin (TTM) Onemednet Corp
-2000% -1500% -1000% -500% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q2: -519.0% FCF margin (TTM), FY24 Q3: -701.5% FCF margin (TTM), FY24 Q4: -1089.1% FCF margin (TTM), FY25 Q1: -1373.9% FCF margin (TTM), FY25 Q2: -1737.8% FCF margin (TTM), FY25 Q3: -1581.6% FCF margin (TTM), FY25 Q4: -552.6% FCF margin (TTM), FY26 Q1: -545.9% FCF margin (TTM), FY26 Q2: -473.4% -473.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -519.0%
FY24 Q3 -701.5%
FY24 Q4 -1089.1%
FY25 Q1 -1373.9%
FY25 Q2 -1737.8%
FY25 Q3 -1581.6%
FY25 Q4 -552.6%
FY26 Q1 -545.9%
FY26 Q2 -473.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 1 1 1 1
Gross profit −0 −0 −0 −1 −1
EBITDA −8 −7 −10 −10 −10
Operating income −8 −7 −10 −10 −10
Net income −30 −34 −10 −3 −9
Diluted EPS −$1.92 −$1.16 −$0.36 −$0.06 −$0.16
Growth (year on year)
Revenue — −11.4% −37.0% +111.4% +216.5%
Margins
Gross margin −31.2% −12.6% −43.7% −37.0% −68.8%
EBITDA margin −667.0% −668.5% <−999% −706.5% −693.3%
Operating margin −669.1% −671.2% <−999% −711.3% −695.7%
Net margin <−999% <−999% <−999% −206.1% −584.2%
Free-cash-flow margin −412.9% −473.6% <−999% −553.1% −473.4%
Cash flow
Cash from operations −5 −5 −7 −8 −7
Capital spending 0 0 0 0 0
Free cash flow −5 −5 −7 −8 −7
Stock-based pay 2 1 1 2 3
Free cash flow after stock pay −7 −6 −8 −10 −9
Balance sheet
Cash 0 0 0 1 0
Total debt 26 2 10 1 1
Net debt (negative = net cash) 26 2 10 0 0
Diluted shares 16m 29m 28m 45m 55m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 5 checks passed · June 30, 2026
What it owns · $1m
Short-term assets $1mLonger-term assets $0m
What it owes, and who funded it · $5m
Short-term liabilities $5mLonger-term liabilities $0mShareholders' equity $-4m
  • Short-term assets cover short-term liabilities $1m of assets due within a year against $5m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1m short-term assets against $156,000 of longer-dated liabilities.
  • More cash than debt $358,000 of cash against $833,000 of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$7m of operating cash flow against $833,000 of debt.
  • Operating profit covers interest at least five times over Operating income of −$10m against $33,000 of interest.

From Onemednet Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+62.6%
year over year
R&D spending
96.2%
of revenue
Days sales outstanding
166 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated ONMD AIFF WORX MNDR DRIO HCTI Median
Revenue, last 12 months $1m $2m $3m $8m $21m $26m $292m
Revenue growth, last 12 months 216.5% 320.3% 3.1% 1.2% −22.6% 116.4% 8.8%
Revenue growth, 3-year average — −41.3% −9.9% — −7.6% −14.9% 0.8%
Revenue growth, latest quarter 88.4% 71.9% 3.4% — −3.6% 158.4% 7.4%
Gross margin −68.8% 44.6% 44.7% 21.2% 58.2% 21.5% 58.6%
Operating margin −695.7% −508.1% −20.1% — −151.6% −57.4% −12.5%
Operating margin, 3-year average <−999% <−999% −36.9% — −213.6% −40.6% −18.8%
Net margin −584.2% −506.2% −80.5% −41.2% −169.9% −66.3% −12.5%
Cash from operations / revenue −472.3% −388.6% −25.5% −19.7% −120.7% −62.4% 9.7%
Free-cash-flow margin −473.4% −388.6% −86.6% −19.7% −121.3% −62.4% 9.2%
Free-cash-flow margin, 3-year average −910.1% <−999% — — −144.7% −44.7% 8.2%
Stock pay / revenue 173.1% 62.0% 9.5% 19.9% 33.6% 3.2% 9.5%
Change in share count 62.6% 27.7% 207.2% 265.5% 25.9% — 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 216.5% 8.8% 2 of 23
Change in growth rate Growth +68.6pp -0.3pp 1 of 23
Gross margin Profitability -68.8% 58.2% 14 of 14
Operating margin Profitability -695.7% -6.6% 22 of 22
Net margin Profitability -584.2% -12.5% 23 of 23
Free-cash-flow margin Cash generation -473.4% 10.6% 22 of 22
Stock pay as % of revenue Cash generation 173.1% 9.7% 22 of 22
Long-term debt as % of assets Balance sheet 9.7% 20.1% 5 of 15
Change in share count Balance sheet 62.6% 2.6% 16 of 19
Days sales outstanding Balance sheet 166 days 58 days 21 of 21

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Data Delivery Revenue $1.3M 92.3% ▲ 329.5%
Subscription Revenue $105,000 7.7% ▼ 70.1%
Geography
Region Revenue Share YoY
EMEA $695,000 51.1% ▲ 187.2%
Americas $608,000 44.7% ▲ 51.6%
Asia Pacific $56,000 4.1% —

From Onemednet Corp's 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$6.9M
Institutions reporting
22
Shares held vs prior quarter
▼ 10.5%
Positions opened / closed
6 / 4

Top buyers and sellers, Q2 2026: 11 institutions bought and 8 sold ; the biggest buyer was Savant Capital, LLC (+7.2M shares) and the biggest seller Citigroup Inc (−135K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Savant Capital, LLC $5.1M 7.2M 75.0% New
Vanguard Capital Management LLC $819,221 1.2M 11.9% ▲ 3.3%
Geode Capital Management, LLC $237,709 334K 3.5% ▼ 1.2%
Vanguard Fiduciary Trust Co $97,909 138K 1.4% ▲ 0.8%
Blackrock, Inc. $86,017 121K 1.3% ▲ 72.6%
State Street Corp $82,974 117K 1.2% 0.0%
Discovery Capital Management, LLC / Ct $79,811 112K 1.2% 0.0%
PNC Financial Services Group, Inc. $73,469 103K 1.1% ▲ 498.7%
Openarc Corporate Advisory, LLC $69,261 97K 1.0% ▲ 758.9%
Northern Trust Corp $33,300 47K 0.5% ▼ 14.8%
Captrust Financial Advisors $23,179 33K 0.3% New
Ashton Thomas Private Wealth, LLC $18,910 27K 0.3% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Onemednet Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $4.2M 14 trades by 3 insiders, last 12 months Insider sales History → $176,918 6 trades by 2 insiders · 0% under pre-set plans
Net ▲ $4M net buying
Insider Date Trade Shares Price Value
Yu Jeffrey Chief Medical Officer October 9, 2026 Buy 45,126 $5.54 $249,998
Kosasa Thomas Director October 7, 2026 Buy 129,758 $5.78 $750,001
Green Aaron Chief Executive Officer September 24, 2026 Sell 1,667 $6.48 $10,802
Green Aaron Chief Executive Officer September 22, 2026 Sell 5,000 $7.39 $36,960
Golden Robert Lawrence Chief Financial Officer September 21, 2026 Sell 3,000 $6.63 $19,890
Golden Robert Lawrence Chief Financial Officer September 15, 2026 Sell 3,000 $6.30 $18,900
Golden Robert Lawrence Chief Financial Officer September 14, 2026 Sell 2,500 $6.60 $16,500
Yu Jeffrey Chief Medical Officer September 10, 2026 Buy 142,857 $0.63 $90,000
Kosasa Thomas Director July 30, 2026 Buy 1,449,275 $0.69 $1M
Yu Jeffrey Chief Medical Officer June 23, 2026 Buy 158,730 $0.63 $100,000
Green Aaron Chief Executive Officer June 23, 2026 Buy 36,650 $0.57 $20,890
Yu Jeffrey Chief Medical Officer June 16, 2026 Buy 172,414 $0.58 $100,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • May 23, 2024

Recent SEC filings

Data status

When each part of this page on Onemednet Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Onemednet Corp in brief

What does Onemednet Corp do?
Onemednet Corp is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Onemednet Corp's stock ticker?
Onemednet Corp trades under the ticker ONMD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Onemednet Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Onemednet Corp reported revenue of $1.5M, 216.5% higher than a year earlier, according to its SEC filings.
What is Onemednet Corp's free cash flow?
Onemednet Corp's free-cash-flow margin is -473.4% of revenue over the trailing twelve months, ranking 22 of the 22 health care technology companies we cover.
Who are Onemednet Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Savant Capital, LLC, Vanguard Capital Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Onemednet Corp's market cap?
On November 2, 2026, Onemednet Corp's market capitalisation was about $234M and net debt of $343,000. Market figures come from third-party market data and may be delayed.
Who are Onemednet Corp's competitors?
In our Health Care Technology peer group, the companies closest to Onemednet Corp are Firefly Neuroscience, Inc., Scworx Corp., Mobile-health Network Solutions, Dariohealth Corp. and Healthcare Triangle, Inc. The side-by-side comparison below sets their revenue, margins and growth against Onemednet Corp's.
Are insiders buying or selling Onemednet Corp stock?
Over the last 12 months, Onemednet Corp's directors and officers reported 14 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.